Controlling Hyperactive Immunity With Long-lived Lymphocytes

计划入组 16 人 · 首次发布于 2026 年 3 月 16 日

Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

计划入组 33 人 · 首次发布于 2022 年 2 月 10 日

Gatekeeper European 005

计划入组 55 人 · 首次发布于 2005 年 9 月 29 日

QEL-002

QEL-001

QEL-ALLO

Respira Therapeutics, Inc.

United States

Antiva Biosciences, Inc.

United States

Intas Pharmaceuticals Ltd.

India

Quell Therapeutics Presents Promising Preclinical Data for QEL-005 CAR-Treg Therapy at ACR Convergence 2025

Quell Therapeutics Launches Phase 1/2 Trial of Novel CAR-Treg Therapy for Autoimmune Diseases

Alumis' A-005 Shows Promise in Phase 1 Trial for CNS Penetration and TYK2 Inhibition